Skip to content
No results
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Strategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • PRMT5 Inhibitor (AT101)
    • Cancer Vaccine (PCV001)
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Strategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • PRMT5 Inhibitor (AT101)
    • Cancer Vaccine (PCV001)
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx

ESMO 2016 Poster 1

May 2, 2016

ESMO-2016-Poster-1

Share This Post

XFacebookLinkedInMessengerWhatsApp

Posts navigation

← Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2) →

More Posts

Interim Phase 2 Results Suggest Zabadinostat Combination Improves Overall Survival in Advanced Liver Cancer

February 26, 2025

IngenOx Therapeutics Chief Medical Officer Meets Chinese Premier to Advance International Anti-Cancer Cooperation

February 10, 2025

IngenOx Therapeutics CMO Receives China Friendship Medal

October 21, 2024
IngenOx

  • Registered Address: Magdalen Centre Oxford Science Park Robert Robinson Avenue Oxford, OX4 4GA
  • Email: enquiries@ingenOx.com

Products

  • Zabadinostat (CXD101)
  • PRMT5 Inhibitor (AT101)
  • Cancer Vaccine (PCV001)
  • Pipeline

About Us

  • About
  • Executive Team
  • Board of Directors
  • Strategic Collaborations

Useful Links

  • Careers
  • Press Releases
  • Publications
  • Contact

Copyright © 2025 

  • Anti-Slavery Statement
  • Privacy Statement